TY - JOUR T1 - An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. AU - Henderson,D C, AU - Kunkel,L, AU - Nguyen,D D, AU - Borba,C P, AU - Daley,T B, AU - Louie,P M, AU - Freudenreich,O, AU - Cather,C, AU - Evins,A E, AU - Goff,D C, PY - 2006/1/21/pubmed PY - 2006/8/3/medline PY - 2006/1/21/entrez SP - 142 EP - 7 JF - Acta psychiatrica Scandinavica JO - Acta Psychiatr Scand VL - 113 IS - 2 N2 - OBJECTIVE: We conducted this 6-week open-label trial to examine the effects of adjunctive aripiprazole in clozapine-treated subjects on weight, lipid and glucose metabolism, as well as positive and negative symptoms of schizophrenia. METHOD: Ten clozapine-treated subjects received aripiprazole augmentation; eight completed the 6-week trial and two ended at week 4. Eighty percent were male, the mean age was 38.7 +/- 8.9 years and the mean clozapine dose was 455 +/- 83 mg daily. RESULTS: There was a significant decrease in weight (P = 0.003), body mass index (P = 0.004), fasting total serum cholesterol (P = 0.002) and total triglycerides (P = 0.04) comparing baseline to study endpoint. There was no significant change in total Positive and Negative Syndrome Scale scores. CONCLUSION: This combination may be useful for clozapine-associated medical morbidity and must be studied in placebo-controlled double-blind randomized trials to determine efficacy and safety. SN - 0001-690X UR - https://www.unboundmedicine.com/medline/citation/16423166/An_exploratory_open_label_trial_of_aripiprazole_as_an_adjuvant_to_clozapine_therapy_in_chronic_schizophrenia_ DB - PRIME DP - Unbound Medicine ER -